checkAd

Cosmos Health Enters the Development Phase for CCX0722, an Innovative Product for Obesity and Weight Management

CHICAGO, IL / ACCESSWIRE / November 29, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC …

CHICAGO, IL / ACCESSWIRE / November 29, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered the development phase for CCX0722, an innovative product for obesity and weight management, based on the effectiveness of biocompatible 3D spatial fillers, from natural ingredients.

Spatial fillers are hydrophilic biopolymer grids capable of absorbing and retaining large amounts of water or biological fluids. Administration of CCX0722 is expected to reduce food intake by increasing satiety and reducing appetite. The product is being optimized in terms of its physicochemical properties and its effects on gut microflora through a series of in vitro studies and simulations. COSMOS plans to initiate clinical intervention in the fourth quarter of 2023.

The product was developed by Cloudpharm PC and collaborators states Dr. Panagiotis Zoumpoulakis, who is also the R&D Advisory Board member for Cosmos Health. Dr. Zoumpoulakis is an associate professor and Head of the department of Food Science and Technology of the University of West Attica, Greece. He holds a bachelor's degree and Ph.D. in Chemistry from the University of Patras and an MBA from the Athens University of Economics and Business. He has authored 130 peer review scientific publications and has been awarded 26 national and European grants.

"The science behind CCX0722 is new and revolutionary in the weight loss space, and our recent trials provide further assurance regarding its effectiveness" stated Greg Siokas, Chief Executive Officer of Cosmos Health. "For years many of our customers and distributors have been searching for a product to fight obesity that is natural, but also effective. We are proud to be one step closer in that endeavor. We are aiming to offer a product for obesity's unmet need with proven efficacy, tolerance and safety documented in clinical trials. We strongly believe that this product can be a leader within this multi-billion dollar market. We are privileged to have the collaboration with Cloudpharm to continue to perfect a product that will usher in a new era for Cosmos Holdings, with a focus on branded pharmaceuticals and medical technologies."

Seite 1 von 3


Nachrichtenquelle: Accesswire
 |  154   |   |   

Schreibe Deinen Kommentar

Disclaimer

Cosmos Health Enters the Development Phase for CCX0722, an Innovative Product for Obesity and Weight Management CHICAGO, IL / ACCESSWIRE / November 29, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC …

Nachrichten des Autors

272 Leser
140 Leser
132 Leser
116 Leser
112 Leser
112 Leser
112 Leser
112 Leser
112 Leser
108 Leser
368 Leser
304 Leser
276 Leser
272 Leser
264 Leser
256 Leser
244 Leser
240 Leser
236 Leser
232 Leser
820 Leser
768 Leser
764 Leser
764 Leser
748 Leser
696 Leser
664 Leser
624 Leser
592 Leser
576 Leser
4532 Leser
2855 Leser
1735 Leser
1585 Leser
1284 Leser
1255 Leser
1244 Leser
1125 Leser
1072 Leser
942 Leser